Aktie A2PWSL PROTALIX BIOTHERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Protalix BioTherapeutics, Inc.

Aktien

A2PWSL

US74365A3095

PLX

Markt geschlossen - Nyse
Andere Börsenplätze
 22:00:00 29.04.2024 		% 5 Tage % 1. Jan.
1,2 USD +4,35 % Intraday Chart für Protalix BioTherapeutics, Inc. +1,69 % -32,58 %
14.03. Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
14.03. Protalix BioTherapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics to Participate in the 2024 BIO CEO and Investor Conference
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Protalix: Q3 Earnings Snapshot
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
Protalix BioTherapeutics : PLX Corporate Presentation (October 2023)
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
Protalix BioTherapeutics : PLX Corporate Presentation (August 2023)
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q2 Revenue $35.1M
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PWSL Aktie
  4. Nachrichten Protalix BioTherapeutics, Inc.
  5. Andere Sprachen